Cancer

Items 21-30 of 44

per page
Set Descending Direction
  1. CD40L [CD154] (human)-muCD8 Fusion Protein (R-PE)
    ANC-505-050.
    ANC-505-05050 tests
    CHF 945.00
  2. DcR3 (human):Fc (human) (rec.)
    CHI-HF-210DcR3
    CHI-HF-210DcR3-C100100 µg
    CHF 460.00
  3. DR6 (human):Fc (human) (rec)
    AG-40B-0011
    AG-40B-0011-C05050 µg
    CHF 170.00
    AG-40B-0011-30503 x 50 µg
    CHF 335.00
  4. Fas (human):Fc (human) (rec.)
    AG-40B-0082
    AG-40B-0082-C05050 µg
    CHF 300.00
    AG-40B-0082-30503 x 50 µg
    CHF 600.00
  5. FasL (human) (multimeric) (rec.)
    AG-40B-0130
    AG-40B-0130-C01010 µg
    CHF 380.00
    AG-40B-0130-30103 x 10 µg
    CHF 760.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No.
  6. FasL, Soluble (human) (rec.)
    AG-40B-0001
    AG-40B-0001-C01010 µg
    CHF 190.00
    AG-40B-0001-30103 x 10 µg
    CHF 385.00
  7. Fc (human):BAFF (human) (rec.)
    AG-40B-0120
    AG-40B-0120-C01010 µg
    CHF 230.00
    AG-40B-0120-30103 x 10 µg
    CHF 460.00
    AG-40B-0120-C500500 µg
    CHF 2'400.00
    Restoration of the splenic T and B cell architecture in Fc-BAFF injected BAFFdeficient mice. BAFF deficient mice were injected at day 0 with 100mg BAFF (human):Fc (human) (AG-40B-0120) intravenously and at day 14 with 50mg BAFF (human):Fc (human) intraper
  8. Fc (human):CD137L, Soluble (human) (rec.)
    AG-40B-0173
    AG-40B-0173-C01010 µg
    CHF 265.00
    AG-40B-0173-30103 x 10 µg
    CHF 530.00
    Fc (human):CD137L, Soluble (human) (rec.) (AG-40B-0173) binds to human CD137. Method: CD137 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of Fc (human):CD137L, Soluble (human) (AG-40B-
  9. Fc (human):FasL, Soluble (human) (rec.)
    AG-40B-0132
    AG-40B-0132-C01010 µg
    CHF 335.00
    AG-40B-0132-30103 x 10 µg
    CHF 670.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Pr
  10. GITR (human):Fc (human) (rec.)
    AG-40B-0028
    AG-40B-0028-C05050 µg
    CHF 385.00
    AG-40B-0028-30503 x 50 µg
    CHF 770.00

Items 21-30 of 44

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.